Innovent Biologics
Corporate brand
UnclaimedA Chinese biopharmaceutical company developing, manufacturing, and commercializing innovative biologic medicines for oncology, autoimmune, metabolic, and other diseases.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Innovent Biologics is a publicly listed Chinese biopharmaceutical company headquartered in Suzhou, Jiangsu. Founded in 2011 by Yu Dechao, the company initially concentrated on the discovery and development of monoclonal antibodies, an area that has become central to modern treatment of cancer, autoimmune disorders, and other serious diseases. Innovent has since expanded into a broader biotechnology platform covering research, clinical development, manufacturing, regulatory affairs, and commercial distribution. The company was established during a period in which China’s pharmaceutical sector was moving from a predominantly generic-drug model toward biologics and internally developed innovative medicines. Innovent’s strategy combined in-house research and development with external financing and partnerships. Early financial backing came from venture investors and strategic institutions, including Eli Lilly and Company, Fidelity Investments, China Life, Hillhouse Capital, and Temasek. These relationships helped support the construction of development and manufacturing capabilities while giving Innovent access to international pharmaceutical expertise and potential commercialization channels. A significant early turning point came in March 2015, when Innovent and Eli Lilly entered an agreement covering the co-development of at least three experimental cancer medicines. The arrangement provided Innovent with an upfront payment and the prospect of additional payments tied to development and commercial achievements. The partnership illustrated Innovent’s dual emphasis on developing medicines for China and establishing commercial links with multinational pharmaceutical companies. Innovent completed its initial public offering on the Hong Kong Stock Exchange in October 2018. The listing provided additional capital for clinical programs, manufacturing infrastructure, and commercialization. Two months later, China approved sintilimab, an anti-PD-1 monoclonal antibody developed by Innovent. Sintilimab became one of the company’s most important products and later formed the basis of a major international licensing arrangement with Eli Lilly. In 2020, Lilly paid an upfront amount for rights outside China and committed additional potential funding linked to development and commercial milestones. The arrangement was subsequently terminated in December 2022 after the United States Food and Drug Administration rejected an application involving sintilimab. Innovent’s portfolio has broadened beyond oncology antibodies. Its activities include biologic therapies and drug candidates in areas such as autoimmune disease and metabolic disorders. In June 2025, China approved mazdutide, a GLP-1 medicine for weight management and diabetes. The approval marked a major expansion into the rapidly developing metabolic-medicine market and was described in the supplied reference material as the first Chinese approval for a domestically developed GLP-1 drug for both weight loss and diabetes. Innovent also partnered with JD Health in connection with distribution of the product. The company’s business model combines product commercialization in China with licensing, co-development, and strategic partnerships for selected assets. In 2025, Sanofi announced an investment in Innovent connected with the joint development of two cancer medicines in China. Later that year, Takeda Pharmaceutical Company announced a much larger collaboration concerning immuno-oncology and antibody-drug-conjugate therapies, including an upfront payment and potential development support. These transactions reflect Innovent’s role as both a domestic commercial biopharmaceutical company and a partner for global pharmaceutical groups seeking access to Chinese innovation and development capabilities. Innovent positions itself around innovation, quality, and improving access to advanced medicines. Its principal business scope includes biologics research and development, clinical testing, regulatory submissions, manufacturing, and commercial sales. The company’s best-known areas have historically been oncology and monoclonal antibodies, while more recent activity has increased its exposure to metabolic medicine. Its present identity is therefore that of an integrated Chinese biopharmaceutical company with a domestic product base and an expanding international partnership network.
History
Innovent Biologics was founded in 2011 by Yu Dechao with an initial emphasis on monoclonal-antibody medicines. Its formation reflected the increasing development of China’s biotechnology sector and the growing importance of biologic therapies in oncology and other serious diseases. Rather than limiting itself to laboratory research, Innovent developed an integrated model spanning discovery, clinical development, manufacturing, regulatory work, and commercialization. The company attracted financial and strategic support from a number of institutional investors, including Eli Lilly and Company, Fidelity Investments, China Life, Hillhouse Capital, and Temasek. Eli Lilly became an especially important partner. In March 2015, the two companies agreed to co-develop at least three experimental cancer medicines. The deal included an upfront payment to Innovent and the possibility of further payments if specified development and commercial milestones were achieved. The agreement helped establish Innovent’s reputation as a Chinese biotechnology company capable of working with major multinational pharmaceutical groups. Innovent went public in October 2018 through an initial public offering on the Hong Kong Stock Exchange. The offering raised capital to support its pipeline and infrastructure. In December of the same year, China approved sintilimab, an anti-PD-1 monoclonal antibody. The product became a major milestone for Innovent and an important part of the company’s oncology strategy. In 2020, Eli Lilly obtained rights outside China to sintilimab through an agreement that included an upfront payment and additional potential funding. The arrangement was intended to support international development and commercialization. In December 2022, Lilly terminated the agreement after the United States Food and Drug Administration rejected an application involving the medicine. The event demonstrated the regulatory and commercial challenges involved in taking an oncology product from the Chinese market into the United States. Innovent subsequently expanded beyond its original oncology-centered identity. Its portfolio and research programs have included autoimmune diseases, metabolic disorders, and additional biologic platforms. In June 2025, mazdutide was approved in China for weight management and diabetes. The approval represented a significant move into GLP-1 medicines and was described in the supplied reference material as the first approval for a Chinese company to market a GLP-1 drug for weight loss and diabetes. Innovent worked with JD Health in relation to distribution. The company also continued to use partnerships to broaden the reach and development resources available to its pipeline. In August 2025, Sanofi announced an investment in Innovent associated with the joint development of two cancer medicines in China. In October 2025, Takeda announced a major agreement involving immuno-oncology and antibody-drug-conjugate therapies, with an upfront payment and a stated aim of accelerating development. These transactions added to Innovent’s international network of pharmaceutical relationships. By the end of the supplied chronology, Innovent had developed from a monoclonal-antibody start-up into an integrated, publicly traded Chinese biopharmaceutical company. Its activities combine domestic commercialization with global licensing and co-development. Oncology remains a defining area, while metabolic medicine has become an increasingly visible growth field. The company’s long-term identity is shaped by its ability to develop biologics in China, obtain regulatory approvals, build manufacturing and commercial capabilities, and collaborate with multinational partners on selected products and technologies.
- 2025
Mazdutide approved in China
[1]Mazdutide received Chinese approval for weight management and diabetes, expanding Innovent into GLP-1 metabolic medicines.
- 2025
Sanofi investment and oncology collaboration
[1]Sanofi announced an investment and a joint development arrangement involving two cancer medicines in China.
- 2025
Takeda immuno-oncology and antibody-drug-conjugate collaboration
[1]Takeda announced a large collaboration intended to accelerate development of immuno-oncology and antibody-drug-conjugate therapies.
- 2022
Termination of Lilly sintilimab agreement
[1]Eli Lilly terminated the international sintilimab agreement after a United States regulatory rejection.
- 2020
International sintilimab rights agreement
[1]Eli Lilly obtained rights outside China to sintilimab under an agreement with upfront and potential milestone-linked payments.
- 2018
Hong Kong listing
[1]Innovent completed its initial public offering and began trading on the Hong Kong Stock Exchange.
- 2018
Sintilimab approved in China
[1]China approved Innovent’s sintilimab anti-PD-1 monoclonal antibody.
- 2015
Initial Eli Lilly oncology collaboration
[1]Innovent and Eli Lilly agreed to co-develop at least three experimental cancer medicines under a milestone-linked arrangement.
- 2011
Company founded
[1]Yu Dechao founded Innovent to develop monoclonal-antibody medicines and other biotechnology products.
Products and positioning
An innovation-led Chinese biopharmaceutical company focused on developing and commercializing high-quality biologic and other innovative medicines, with core strengths in oncology and growing activity in autoimmune and metabolic diseases.
Anti-PD-1 monoclonal antibody · 2018
Sintilimab
Sintilimab is an anti-PD-1 monoclonal antibody and one of Innovent’s principal oncology products. It was approved in China in December 2018. The medicine became the subject of an international development and commercialization agreement with Eli Lilly in 2020, although that agreement was terminated in 2022 after a United States regulatory rejection.
Biosimilar monoclonal antibody
Bevacizumab biosimilar
Innovent’s portfolio includes a bevacizumab biosimilar, representing the company’s work in oncology biologics and its broader effort to provide high-quality biologic treatments. Bevacizumab-based therapies target vascular endothelial growth factor pathways and are used across several cancer-treatment settings. Specific launch and current regulatory details are not provided in the supplied reference material.
GLP-1 metabolic medicine · 2025
Mazdutide
Mazdutide is a GLP-1 medicine developed for metabolic indications including weight management and diabetes. China approved the product in June 2025. Its approval marked Innovent’s expansion beyond its historical oncology concentration, and the company partnered with JD Health in connection with distribution.
Controversies
Marketing campaigns
- 2025Mazdutide distribution partnership with JD Health
China
Innovent partnered with JD Health to support distribution of mazdutide following its Chinese approval for weight management and diabetes.
Outcome. Distribution partnership reported; detailed campaign performance is not provided.
Brand decisions
2025
Expand into GLP-1 metabolic medicines with mazdutideProduct launchBackground
Innovent broadened its business beyond its established oncology and antibody focus into the fast-growing metabolic-medicine market.
Action taken
The company obtained Chinese approval for mazdutide for weight management and diabetes and arranged distribution support with JD Health.
Aftermath
Mazdutide became a prominent part of Innovent’s metabolic portfolio and extended its commercial scope beyond oncology.
2025
Partner with Sanofi on two cancer medicinesM&ABackground
Innovent continued to use strategic partnerships to fund and accelerate development of oncology assets in China.
Action taken
Sanofi announced an investment in Innovent connected with joint development of two cancer drugs in China.
Aftermath
The arrangement strengthened Innovent’s relationship with a global pharmaceutical company; detailed development outcomes were not provided.
Sanofi investment. $307.88 million (August 2025)
2025
Enter Takeda immuno-oncology and antibody-drug-conjugate collaborationM&ABackground
Innovent sought to accelerate development of advanced oncology therapies through a large international pharmaceutical partnership.
Action taken
Takeda announced an agreement with Innovent covering immuno-oncology and antibody-drug-conjugate cancer therapies.
Aftermath
The agreement expanded Innovent’s international collaboration network and provided a platform for further development of selected cancer programs.
Transaction value and upfront payment. $11.4 billion total deal value, including a $1.2 billion upfront payment (October 2025)
2020
Grant Eli Lilly rights outside China to sintilimabM&ABackground
Innovent pursued international development and commercialization of its lead oncology product through a multinational pharmaceutical partner.
Action taken
Innovent granted Eli Lilly rights outside China to sintilimab under a payment and milestone arrangement.
Aftermath
Lilly later terminated the agreement in December 2022 after a United States regulatory rejection.
Upfront and potential milestone payments. $200 million upfront and up to $825 million in potential additional payments (2020 agreement)
2018
List on the Hong Kong Stock ExchangeOtherBackground
Innovent required additional capital to fund its pipeline, infrastructure, and commercialization activities.
Action taken
The company completed an initial public offering on the Hong Kong Stock Exchange.
Aftermath
Innovent became a publicly traded biopharmaceutical company and gained access to public-market financing.
IPO proceeds. $421 million raised (October 2018)
2015
Enter cancer-drug co-development agreement with Eli LillyM&ABackground
Innovent sought external resources and multinational collaboration to advance a group of experimental oncology medicines.
Action taken
The companies agreed to co-develop at least three experimental cancer drugs under upfront and milestone-linked financial terms.
Aftermath
The agreement established an important strategic relationship between Innovent and Eli Lilly and preceded the later international licensing arrangement for sintilimab.
Upfront payment and potential milestone payments. $56 million upfront; more than $400 million in potential additional payments (2015 agreement)
Recent events
- Unconfirmed
Innovent Biologics and Takeda announce global strategic partnership[3]
Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to develop potential first-in-class targeted innovative drugs. Upfront and milestone payments total more than US$1 billion.
Reported
Innovent and Lilly deepen oncology partnership in China[4]
Innovent and Lilly announced an agreement deepening their oncology partnership. Innovent will receive exclusive commercialization rights in mainland China after approval for Cyramza and Retsevmo, and priority negotiation rights for future commercialization of Pirtobrutinib in mainland China.
Reported
Innovent and Ascentage announce strategic collaboration[5]
Innovent Biologics and Ascentage Pharma announced a strategic collaboration covering joint commercialization in China of HQP1351 after approval, exploration of clinical co-development for several medicines, and an equity investment in Ascentage Pharma.
Reported
NMPA approves SULINNO in China[6]
China's National Medical Products Administration approved Innovent Biologics' adalimumab injection SULINNO for marketing to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
Reported
Innovent and Lilly expand sintilimab collaboration globally[7]
Innovent Biologics and Eli Lilly announced an expansion of their strategic collaboration on sintilimab: Innovent granted Lilly an exclusive license for the drug outside China, and Lilly will work to bring it to North America, Europe and other regions. The agreement is subject to customary closing conditions, including U.S. antitrust approval.
- Unconfirmed
Reported
Innovent Biologics and Geneseeq formed a companion-diagnostics partnership[8]
Innovent Biologics and Beijing Geneseeq Technology entered a strategic collaboration to jointly develop and commercialize companion diagnostic reagents in China for pemigatinib, for detecting FGFR2 gene fusion or rearrangement mutations in patients with cholangiocarcinoma.
Reported
Innovent and Roche enter strategic collaboration[9]
Innovent Biologics, through its wholly owned subsidiary Innovent Biologics (HK) Limited, entered a strategic collaboration with Roche focused on research, clinical development and commercialization of bispecific antibody and cell therapy products.
Reported
Innovent Biologics and MD Anderson announce strategic collaboration on sintilimab[10]
Innovent Biologics and MD Anderson Cancer Center announced a strategic collaboration to jointly develop sintilimab in the United States for multiple rare cancers. The partners will jointly bear development costs, which may include multiple clinical studies conducted by MD Anderson.
Reported
Innovent and Alector partner on AL008 in China[11]
Innovent Biologics and Alector announced a collaboration under which Innovent received rights to develop and commercialize Alector's AL008 antibody in China, including Hong Kong, Macao, and Taiwan. Innovent will lead development and commercialization in China, including manufacturing; Alector will lead development outside China.
Reported
Innovent and Alector announce AL008 collaboration in China[12]
Innovent Biologics and Alector announced a collaboration under which Innovent received rights to develop and commercialize Alector’s anti-SIRP-alpha antibody AL008 in China, including Hong Kong, Macau and Taiwan. Innovent will lead development and commercialization in China, including product manufacturing, while Alector will lead development outside China.
Sources15 sources
- 1Innovent Biologicsen.wikipedia.org
- 2Innovent Biologics official websiteinnoventbio.com
- 3信达生物与武田制药宣布全球战略合作fund.jrj.com.cn
- 4信达生物与礼来深化中国肿瘤领域合作prnasia.com
- 5信达生物与亚盛医药宣布达成战略合作prnasia.com
- 6苏立信获批在中国上市finance.sina.com.cn
- 7信达生物与礼来扩大达伯舒全球合作finance.sina.com.cn
- 8信达生物与吉因加达成伴随诊断战略合作prnasia.com
- 9信达生物与罗氏达成战略合作tech.sina.com.cn
- 10信达生物与MD Anderson癌症中心宣布合作开发信迪利单抗prnasia.com
- 11信达生物与Alector合作开发和商业化AL008prnasia.com
- 12信达生物与Alector宣布AL008中国合作finance.sina.com.cn
- 13信达生物与圣诺制药宣布临床研究合作nbd.com.cn
- 14信达生物与礼来制药宣布扩大关于达伯舒的全球战略合作 第一次中国自主研发的已上市大分子药物转让给世界500强药企finance.sina.com.cn
- 15亚盛医药与信达生物达成2.45亿美元战略合作，涉及HQP1351中国商业推广、APG-2575联合临床开发、股权投资等多领域prnasia.com
Cite this profile: Cite the canonical profile. /brand-wiki/innovent-biologics · Editorial policy · How profiles are compiled